James Wymer

James Wymer, MD, FAAN

Professor & Division Chief; Melvin Greer Professor

Department: MD-NEUROMUSCULAR NEUROLOGY
Business Phone: (352) 273-5550

About James Wymer

My name is Dr. James Wymer, I’m a neurologist and professor practicing at the University of Florida. I specialize in diagnosis and management of neuromuscular diseases, including amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease, muscle diseases, and peripheral neuropathies. I have extensive experience in clinical research, having been a principal investigator on numerous clinical trials, including studies of ALS, diabetic neuropathy, multiple sclerosis, migraine headaches, and epilepsy. I am a fellow of the American Academy of Neurology (AAN) and the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM), as well as a member of several national consortiums to research neuropathic pain and ALS.

My clinical interests include: • ALS or Lou Gehrig’s Disease • Neuromuscular diseases • Hereditary Neuropathy • Muscle disease • Multiple Sclerosis • Diabetic neuropathy • Migraine headaches • Neurofibromatosis

Teaching Profile

Courses Taught
2021
PAS5020 Intro to Medicine 2
2021
MDC7800 Neurology Clerkship

Board Certifications

  • Neurology
    American Board of Psychiatry and Neurology

Clinical Profile

Specialties
  • Neurology
Subspecialties
  • Neuromuscular Medicine
Areas of Interest
  • Amyotrophic lateral sclerosis (ALS)
  • Migraine
  • Multiple sclerosis
  • Neurofibromatosis 2
  • Neurofibromatosis-1
  • Neuromuscular disorders
  • Peripheral neuropathy

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0003-0809-2977

Areas of Interest
  • ALS
  • Muscular dystrophy
  • Neuropathy

Publications

2023
Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis.
Annals of clinical and translational neurology. 10(8):1296-1304 [DOI] 10.1002/acn3.51821. [PMID] 37265174.
2023
Functional Lingual Pressure Thresholds for Swallowing Safety and Efficiency Impairments in Amyotrophic Lateral Sclerosis.
Dysphagia. 38(2):676-685 [DOI] 10.1007/s00455-022-10499-1. [PMID] 35907088.
2023
Maximum lingual pressure impacts both swallowing safety and efficiency in individuals with amyotrophic lateral sclerosis
Neurogastroenterology & Motility. 35(4) [DOI] 10.1111/nmo.14521. [PMID] 36573040.
2023
Maximum Phonation Time as a Surrogate Marker for Airway Clearance Physiologic Capacity and Pulmonary Function in Individuals With Amyotrophic Lateral Sclerosis.
Journal of speech, language, and hearing research : JSLHR. 66(4):1165-1172 [DOI] 10.1044/2022_JSLHR-22-00522. [PMID] 36877985.
2023
Oral Edaravone – Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.
Expert review of neurotherapeutics. 23(10):859-866 [DOI] 10.1080/14737175.2023.2251687. [PMID] 37646130.
2023
Pharmacokinetics, Bioavailability, and Swallowing Safety With Riluzole Oral Film.
Clinical pharmacology in drug development. 12(1):57-64 [DOI] 10.1002/cpdd.1168. [PMID] 36168148.
2023
Predictors of Peak Expiratory Cough Flow in Individuals with Amyotrophic Lateral Sclerosis.
Dysphagia. 38(2):719-725 [DOI] 10.1007/s00455-022-10503-8. [PMID] 35931882.
2023
Primary lateral sclerosis natural history study – planning, designing, and early enrollment.
Amyotrophic lateral sclerosis & frontotemporal degeneration. 24(5-6):394-404 [DOI] 10.1080/21678421.2022.2161912. [PMID] 36576200.
2023
Profiles of Dysarthria and Dysphagia in Individuals With Amyotrophic Lateral Sclerosis.
Journal of speech, language, and hearing research : JSLHR. 66(1):154-162 [DOI] 10.1044/2022_JSLHR-22-00312. [PMID] 36525626.
2023
Profiling Number of Swallows per Bolus and Residue in Individuals With Amyotrophic Lateral Sclerosis.
Journal of speech, language, and hearing research : JSLHR. 66(10):3763-3772 [DOI] 10.1044/2023_JSLHR-23-00209. [PMID] 37591233.
2023
Respiratory Strength Training in Amyotrophic Lateral Sclerosis
Neurology. 100(15) [DOI] 10.1212/wnl.0000000000206830.
2023
Respiratory therapies for Amyotrophic Lateral Sclerosis: A state of the art review.
Chronic respiratory disease. 20 [DOI] 10.1177/14799731231175915. [PMID] 37219417.
2023
Sensitivity and specificity of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised to detect dysarthria in individuals with amyotrophic lateral sclerosis.
Muscle & nerve. 68(3):296-302 [DOI] 10.1002/mus.27923. [PMID] 37345346.
2023
Temporal serum metabolomic and lipidomic analyses distinguish patients with access-related hand disability following arteriovenous fistula creation.
Scientific reports. 13(1) [DOI] 10.1038/s41598-023-43664-z. [PMID] 37798334.
2023
The natural history of ALS: Baseline characteristics from a multicenter clinical cohort
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24(7-8):625-633 [DOI] 10.1080/21678421.2023.2232812.
2022
Acute intermittent hypoxia and respiratory muscle recruitment in people with amyotrophic lateral sclerosis: A preliminary study.
Experimental neurology. 347 [DOI] 10.1016/j.expneurol.2021.113890. [PMID] 34624328.
2022
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
Molecular Neurodegeneration. 17(1) [DOI] 10.1186/s13024-022-00515-1. [PMID] 35073950.
2022
Discriminant ability of the 3-ounce water swallow test to detect aspiration in amyotrophic lateral sclerosis.
Neurogastroenterology and motility. 34(7) [DOI] 10.1111/nmo.14310. [PMID] 34936158.
2022
Discriminant Ability of the Eating Assessment Tool-10 to Detect Swallowing Safety and Efficiency Impairments.
The Laryngoscope. 132(12):2319-2326 [DOI] 10.1002/lary.30043. [PMID] 35137963.
2022
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial.
Journal of neurology, neurosurgery, and psychiatry. 93(8):871-5 [DOI] 10.1136/jnnp-2022-329024. [PMID] 35577511.
2022
Swallowing Safety and Efficiency Impairment Profiles in Individuals with Amyotrophic Lateral Sclerosis.
Dysphagia. 37(3):644-654 [DOI] 10.1007/s00455-021-10315-2. [PMID] 34037850.
2021
A case of diffuse midline glioma with histone H3 K27M mutation mimicking long segmental myelitis
Interdisciplinary Neurosurgery. 23 [DOI] 10.1016/j.inat.2020.101005.
2021
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS.
Amyotrophic lateral sclerosis & frontotemporal degeneration. 22(3-4):287-299 [DOI] 10.1080/21678421.2020.1822410. [PMID] 32969758.
2021
Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.
Muscle & nerve. 63(1):31-39 [DOI] 10.1002/mus.27091. [PMID] 33063909.
2021
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
JAMA neurology. 78(1):68-76 [DOI] 10.1001/jamaneurol.2020.2590. [PMID] 32809014.
2021
Reflexive Airway Sensorimotor Responses in Individuals with Amyotrophic Lateral Sclerosis.
Dysphagia. 36(4):574-582 [DOI] 10.1007/s00455-020-10171-6. [PMID] 32778945.
2020
Clinical care and therapeutic trials in PLS.
Amyotrophic lateral sclerosis & frontotemporal degeneration. 21(sup1):67-73 [DOI] 10.1080/21678421.2020.1837180. [PMID] 33602017.
2020
Diagnostic utility of the amyotrophic lateral sclerosis Functional Rating Scale-Revised to detect pharyngeal dysphagia in individuals with amyotrophic lateral sclerosis.
PloS one. 15(8) [DOI] 10.1371/journal.pone.0236804. [PMID] 32790801.
2020
Management of Primary Lateral Sclerosis
Current Treatment Options in Neurology. 22(10) [DOI] 10.1007/s11940-020-00640-6.
2020
Preface: promoting research in PLS: current knowledge and future challenges.
Amyotrophic lateral sclerosis & frontotemporal degeneration. 21(sup1):1-2 [DOI] 10.1080/21678421.2020.1840795. [PMID] 33602018.
2020
Sleep disorders in myotonic dystrophies.
Muscle & nerve. 62(3):309-320 [DOI] 10.1002/mus.26866. [PMID] 32212331.
2020
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
The New England journal of medicine. 383(10):919-930 [DOI] 10.1056/NEJMoa1916945. [PMID] 32877582.
2019
Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis.
Muscle & nerve. 59(5):531-536 [DOI] 10.1002/mus.26408. [PMID] 30620104.
2018
Best practices protocol for the evaluation of bulbar dysfunction: summary recommendations from the NEALS bulbar subcommittee symposium.
Amyotrophic lateral sclerosis & frontotemporal degeneration. 19(3-4):311-312 [DOI] 10.1080/21678421.2017.1404109. [PMID] 29205054.
2018
Combined respiratory training in an individual with C9orf72 amyotrophic lateral sclerosis.
Annals of clinical and translational neurology. 5(9):1134-1138 [DOI] 10.1002/acn3.623. [PMID] 30250869.
2018
Targeting the Neuromuscular Junction in ALS.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 15(3):713-714 [DOI] 10.1007/s13311-018-0647-y. [PMID] 30006767.
2017
Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 14(3):762-772 [DOI] 10.1007/s13311-016-0508-5. [PMID] 28070747.
2017
Erratum to: Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 14(3) [DOI] 10.1007/s13311-017-0517-z. [PMID] 28283968.
2017
Increasing Evidence for an Association Between Amyotrophic Lateral Sclerosis and Psychiatric Disorders.
JAMA neurology. 74(12):1396-1398 [DOI] 10.1001/jamaneurol.2017.1920. [PMID] 29049449.
2017
Paraneoplastic Lambert-Eaton Myasthenic Syndrome With Limbic Encephalitis: Clinical Correlation With the Coexistence of Anti-VGCC and Anti-GABAB Receptor Antibodies.
Journal of clinical neuromuscular disease. 19(2):84-88 [DOI] 10.1097/CND.0000000000000192. [PMID] 29189554.
2017
The evaluation of bulbar dysfunction in amyotrophic lateral sclerosis: survey of clinical practice patterns in the United States.
Amyotrophic lateral sclerosis & frontotemporal degeneration. 18(5-6):351-357 [DOI] 10.1080/21678421.2017.1313868. [PMID] 28425762.
2015
Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy.
Annals of clinical and translational neurology. 2(5):465-78 [DOI] 10.1002/acn3.186. [PMID] 26000320.
2014
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
Current medical research and opinion. 30(11):2255-65 [DOI] 10.1185/03007995.2014.940040. [PMID] 25062507.
2011
Keratinocyte expression of calcitonin gene-related peptide β: implications for neuropathic and inflammatory pain mechanisms.
Pain. 152(9):2036-2051 [DOI] 10.1016/j.pain.2011.04.033. [PMID] 21641113.
2009
Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.
The Clinical journal of pain. 25(5):376-85 [DOI] 10.1097/AJP.0b013e318196d2b6. [PMID] 19454870.
2006
Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.
Clinical therapeutics. 28(10):1607-18 [PMID] 17157116.
2006
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
Annals of neurology. 59(5):780-7 [PMID] 16634036.

Grants

Dec 2023 ACTIVE
ALS/MND NATURAL HISTORY REPOSITORY SITE AGREEMENT
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL
Sep 2023 ACTIVE
Clinic-based Multicenter ALS Natural History Data Collection- Supplement
Role: Principal Investigator
Funding: UNIV OF MINNESOTA via US FOOD AND DRUG ADMN
Sep 2023 ACTIVE
Safety of Metformin in C9orf72 ALS: Effects on RAN Proteins, Breathing, Imaging, and Metabolomic Outcome Measures
Role: Co-Investigator
Funding: US ARMY MED RES ACQUISITION
Apr 2023 ACTIVE
A Phase 2, randomised, double-blind, placebo-controlled, 2-way crossover study to evaluate the efficacy, safety, and tolerability of NMD670 in ambulatory adults with Type 3 spinal muscular atrophy
Role: Principal Investigator
Funding: NMD PHARMA
Dec 2022 ACTIVE
Safety & therapeutic potential of metformin for C9orf72 ALS
Role: Co-Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Nov 2022 ACTIVE
CTOA Wymer – Residuals ?
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Sep 2022 ACTIVE
Clinic-based Multicenter ALS Natural History Data Collection
Role: Principal Investigator
Funding: UNIV OF MINNESOTA via US FOOD AND DRUG ADMN
Aug 2022 ACTIVE
A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC via MITSUBISHI TANABE PHARMA DEVELOPMENT
Aug 2022 ACTIVE
PLS Natural History Project 2
Role: Principal Investigator
Funding: COLUMBIA UNIVERSITY MEDICAL CENTER via AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Jul 2022 ACTIVE
Identifying and targeting novel repeat associated non-AUG (RAN) proteins in sporadic ALS
Role: Co-Investigator
Funding: US ARMY MED RES ACQUISITION
Jul 2022 ACTIVE
Novel repeat associated non-AUG (RAN) proteins in sALS, sFTD and SBMA: shared pathological features and unifying therapeutic opportunities
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Jun 2022 ACTIVE
An Intermediate size, Expanded Access Protocol to Provide AMX0035, a Fixed Combination of Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO), for the Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: BIONICAL LTD via AMYLYX PHARMACEUTICALS
Jan 2022 ACTIVE
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: PEACHTREE BIORESEARCH SOLUTIONS via AMYLYX PHARMACEUTICALS
Jan 2022 ACTIVE
Acute adenosine receptor antagonism to promote breathing plasticity in ALS
Role: Co-Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Jul 2021 ACTIVE
CTOA – Multiple Sclerosis
Role: Principal Investigator
Funding: UNIV OF FLORIDA
May 2021 ACTIVE
Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic study of Intravenous ANX005 in Subjects with Amyotrophic Lateral Sclerosis
Role: Principal Investigator
Funding: WORLDWIDE CLINICAL TRIALS via ANNEXON
Apr 2021 ACTIVE
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
Role: Principal Investigator
Funding: WORLDWIDE CLINICAL TRIALS via PHARNEXT
Mar 2021 ACTIVE
A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC via MITSUBISHI TANABE PHARMA DEVELOPMENT
Dec 2020 ACTIVE
A Phase 3, Multi-Center, Open-label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC via MITSUBISHI TANABE PHARMA DEVELOPMENT
Nov 2020 ACTIVE
A pharmacokinetic and pharmacodynamic study of AMX0035 in patients with ALS
Role: Principal Investigator
Funding: AMYLYX PHARMACEUTICALS
Oct 2020 ACTIVE
A Compassionate Use Protocol of AMX0035 for treatment of patients with Amyotrophic Lateral Sclerosis
Role: Principal Investigator
Funding: UNITED BIOSOURCE via AMYLYX PHARMACEUTICALS
Jul 2020 – Jul 2022
PLS Natural History Study (PNHS)
Role: Principal Investigator
Funding: COLUMBIA UNIVERSITY via SPASTIC PARAPLEGIA FOUNDATION
Feb 2020 – Nov 2022
A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC via MITSUBISHI TANABE PHARMA DEVELOPMENT
Jan 2020 – Jan 2025
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients with ALS: Open-Label Extension for Patients Completing Study 3119002
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO via ORION CORP
Jan 2020 ACTIVE
HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) A to Master Protocol, ZILUCOPLAN | Home Spirometry and Open-Label Extension (OLE) Period (add'l support for TO2)
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL via RA PHARMACEUTICALS
Jan 2020 ACTIVE
Platform Trial for the Treatment of Amyotrophic Lateral Sclerosis (A LS): A perpetual multi-center, multi-regimen, clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL
Jan 2020 – Dec 2021
Quality of Life Grant MS Foundation
Role: Principal Investigator
Funding: MULTIPLE SCLEROSIS FOUNDATION
Jan 2020 – Jun 2020
Natural History Pilot Project- University of Florida
Role: Principal Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Sep 2019 ACTIVE
Surveillance of muscular dystrophy in the Southeastern United States
Role: Co-Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Nov 2018 ACTIVE
CTOA – General
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Aug 2018 – Aug 2023
EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES via ORION CORP
Apr 2018 – Feb 2023
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for Treatment of Amyotrophic Lateral Sclerosis (ALS), Open Label Extension
Role: Principal Investigator
Funding: AMYLYX PHARMACEUTICALS
Jan 2018 – Jan 2023
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CK 2127107 in Patients with Amyotrophic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL CORP via CYTOKINETICS INC
Jan 2018 – Jan 2023
A Single Center Study to Evaluate the Effect of Riluzole Oral Soluble Film on Swallowing Safety in Individuals With Amyotrophic Lateral Sclerosis
Role: Principal Investigator
Funding: INVENTIV HEALTH CLINICAL LLC via AQUESTIVE THERAPEUTICS
Dec 2017 – Dec 2022
A multicenter, 18-week open label safety and efficacy trial of Dalfampridine in primary lateral sclerosis
Role: Principal Investigator
Funding: HOSPITAL FOR SPECIAL SURGERY via NORTHEAST ALS ASSO
Nov 2017 – Nov 2018
A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects with Charcot-Marie-Tooth Disease
Role: Principal Investigator
Funding: FLEX PHARMA INC
Oct 2017 – Oct 2022
A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar? Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis
Role: Principal Investigator
Funding: *MALLINCKRODT PHARMACEUTICALS-Bankrupt
Jul 2017 – Aug 2023
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA) for a Treatment of Amyotropic Lateral Sclerosis (ALS)
Role: Principal Investigator
Funding: MASSACHUSETTS GENERAL HOSPITAL via AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Jul 2017 – May 2022
A Program to develop a research database for the study of abnormal cellular components in Myasthenia Gravis: Specimen banking and data registry
Role: Principal Investigator
Funding: UF FOUNDATION
Apr 2017 – Mar 2023
Delineating Physiologic Mechanisms of Swallowing impairment and Decline in ALS
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2016 – Jul 2021
A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects with Painful Diabetic Peripheral Neuropathy
Role: Principal Investigator
Funding: VIROMED CO LTD
Apr 2014 – Sep 2018
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)
Role: Principal Investigator
Funding: UNIV OF KANSAS MEDICAL CTR via PATIENT-CENTERED OUTCOMES RES INST

Education

Medical Degree
1984-1991 · University of Maryland

Contact Details

Phones:
Business:
(352) 273-5550
Emails:
Addresses:
Business Mailing:
PO Box 100268
GAINESVILLE FL 32610
Business Street:
3011 SW WILLISTON RD RM 1103
GAINESVILLE FL 32608